TapewireFind a company

person · Reporting owner

Bizily Scott

Disclosed activity across 1 company

Tapewire entity
2420
SEC CIK
0001920738

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
4D Molecular Therapeutics, Inc.FDMT · Entity 2419Chief Legal OfficerSeptember 16, 2026September 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

4D Molecular Therapeutics, Inc.

Report date September 16, 2026 · Filed September 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect8,617 Ending reported balance After 2026-09-16 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-16 · Exercise / conversion · Acquired 1,635 · Balance 10,252

Row 2 · 2026-09-16 · Sale · Disposed 1,635 · Balance 8,617

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05Direct58,066 Reported balance After 2026-09-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-09-16 · Exercise / conversion · Disposed 1,635 · Balance 58,066

F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.

F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 01, 2024 Filed Jul 3, 2024 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 2,916 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-081626 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,752

Underlying: Common Stock · 2,916 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,332 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-081626 · ownership.xml · derivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,879

Underlying: Common Stock · 1,332 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 4,248 $21.36 $90,757.67
Disclosure

SEC source: 0000950170-24-081626 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $21.01 to $21.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 2,916 $8.04 $23,444.64
Disclosure

SEC source: 0000950170-24-081626 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,332 $6.49 $8,644.68
Disclosure

SEC source: 0000950170-24-081626 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,069

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:59 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,250 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-075692 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,668

Underlying: Common Stock · 1,250 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:59 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 500 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-075692 · ownership.xml · derivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,211

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:59 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,750 $23.71 $41,493.55
Disclosure

SEC source: 0000950170-24-075692 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $23.45 to $24.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:59 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,250 $8.04 $10,050.00
Disclosure

SEC source: 0000950170-24-075692 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:59 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 500 $6.49 $3,245.00
Disclosure

SEC source: 0000950170-24-075692 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
May 16, 2024 Filed May 21, 2024 00:35 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,250 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-062637 · ownership.xml · derivative · entry 6

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,918

Underlying: Common Stock · 1,250 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F5 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
May 16, 2024 Filed May 21, 2024 00:35 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 500 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-062637 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,711

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
May 16, 2024 Filed May 21, 2024 00:35 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 467 $25.75 $12,027.26
Disclosure

SEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · price: The transaction was executed in multiple trades in prices ranging from $25.67 to $25.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
May 16, 2024 Filed May 21, 2024 00:35 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,283 $25.34 $32,513.79
Disclosure

SEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,204

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $24.67 to $25.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote..

Read SEC document
May 16, 2024 Filed May 21, 2024 00:35 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,250 $8.04 $10,050.00
Disclosure

SEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
May 16, 2024 Filed May 21, 2024 00:35 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 500 $6.49 $3,245.00
Disclosure

SEC source: 0000950170-24-062637 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:48 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,250 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-045702 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,168

Underlying: Common Stock · 1,250 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:48 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 500 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-045702 · ownership.xml · derivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,211

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:48 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,750 $25.74 $45,045.00
Disclosure

SEC source: 0000950170-24-045702 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:48 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,250 $8.04 $10,050.00
Disclosure

SEC source: 0000950170-24-045702 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:48 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 500 $6.49 $3,245.00
Disclosure

SEC source: 0000950170-24-045702 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,909 $0.00 Strike: $20.24 $0.00
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 9

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,182

Underlying: Common Stock · 1,909 shares

Expires 2033-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F5 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,996 $0.00 Strike: $15.78 $0.00
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 8

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,008

Underlying: Common Stock · 1,996 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 2,916 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 7

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,418

Underlying: Common Stock · 2,916 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,332 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · derivative · entry 6

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,711

Underlying: Common Stock · 1,332 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 8,153 $31.78 $259,102.34
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,909 $20.24 $38,638.16
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,996 $15.78 $31,496.88
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,981

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 2,916 $8.04 $23,444.64
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,985

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 23:18 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,332 $6.49 $8,644.68
Disclosure

SEC source: 0000950170-24-041418 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,069

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 20:52 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,491 $0.00 Strike: $25.98 $0.00
Disclosure

SEC source: 0000950170-24-038731 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,167

Underlying: Common Stock · 1,491 shares

Expires 2031-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 20:52 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 4,342 $0.00 Strike: $25.98 $0.00
Disclosure

SEC source: 0000950170-24-038731 · ownership.xml · derivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,658

Underlying: Common Stock · 4,342 shares

Expires 2031-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 20:52 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 5,833 $35.04 $204,410.49
Disclosure

SEC source: 0000950170-24-038731 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 20:52 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,491 $25.98 $38,736.18
Disclosure

SEC source: 0000950170-24-038731 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 20:52 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 4,342 $25.98 $112,805.16
Disclosure

SEC source: 0000950170-24-038731 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,079

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:40 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,250 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-034227 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,334

Underlying: Common Stock · 1,250 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:40 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 500 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-034227 · ownership.xml · derivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,043

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:40 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,750 $31.27 $54,722.50
Disclosure

SEC source: 0000950170-24-034227 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:40 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,250 $8.04 $10,050.00
Disclosure

SEC source: 0000950170-24-034227 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:40 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 500 $6.49 $3,245.00
Disclosure

SEC source: 0000950170-24-034227 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:01 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,909 $0.00 Strike: $20.24 $0.00
Disclosure

SEC source: 0000950170-24-023330 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,091

Underlying: Common Stock · 1,909 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:01 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,909 $30.00 $57,270.00
Disclosure

SEC source: 0000950170-24-023330 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:01 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,909 $20.24 $38,638.16
Disclosure

SEC source: 0000950170-24-023330 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,646

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 22:41 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,250 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-018155 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,584

Underlying: Common Stock · 1,250 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 22:41 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 500 $0.00 Strike: $6.49 $0.00
Disclosure

SEC source: 0000950170-24-018155 · ownership.xml · derivative · entry 4

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,543

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 22:41 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,750 $27.67 $48,422.50
Disclosure

SEC source: 0000950170-24-018155 · ownership.xml · nonDerivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 22:41 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,250 $8.04 $10,050.00
Disclosure

SEC source: 0000950170-24-018155 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 22:41 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 500 $6.49 $3,245.00
Disclosure

SEC source: 0000950170-24-018155 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,237

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:04 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right to Buy) · Derivative 1,996 $0.00 Strike: $15.78 $0.00
Disclosure

SEC source: 0000950170-24-014119 · ownership.xml · derivative · entry 9

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,004

Underlying: Common Stock · 1,996 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:04 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right to Buy) · Derivative 2,916 $0.00 Strike: $8.04 $0.00
Disclosure

SEC source: 0000950170-24-014119 · ownership.xml · derivative · entry 8

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,834

Underlying: Common Stock · 2,916 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.